Account
Hero background pattern

We’ll launch your pharmaceuticals to new heights

Specialist and experienced pricing and market access consultancy

Articles

What are the 5 Pricing & Market Access trends…

Our experts provide an overview of the five key trends that could shape the pricing and market acces…
Read more
News

ISPOR Europe 2023

We’re thrilled to announce our participation at ISPOR Europe 2023 in Copenhagen this November. We’ll…
Read more
Insider Insights

Worldwide: New Coalition to improve access to canc…

According to the UICC, “priority will be given to medicines currently on the WHO Essential Medicin…
Read more
Insider Insights

World’s first CRISPR medicine approved in UK for…

The MHRA grants conditional approval to Casgevy, the first-ever CRISPR gene-editing therapy for sick…
Read more
Articles

World Orphan Drug Congress Europe 2023 REPORT

We summarise the World Orphan Drug Congress Europe 2023 including keynote and panel sessions on EU H…
Read more
161 Pharma & biotech companies worked with
11 We work with 11 of the top 20 pharma companies
95% Positive feedback from our training courses
57 We’ve supported pricing and access strategies in 57 countries worldwide

Our Services

From launching your product to access training

Launch Implementation

We will develop and implement a successful launch strategy for your product.

Find out more

Price Optimization

We build payer focussed pricing and market access strategies to enable commercial success.

Find out more

Market Access Training

We provide engaging training solutions that ensures your organisation stays ahead of the ever-changing market access landscape.

Find out more

Our mission

To enable patient access to your products

Unifying our internal strengths and external partnerships helps solve your pricing and market access challenges to drive patient access of your pharmaceutical products.

Our strategy

We have the expertise to get your products into doctors hands

Clearly and concisely communicate key scientific, economic and commercial messages to enable company employees to effectively communicate the product’s value.

How we work

Bespoke approach

Individual solutions to suit you

Flexible

We adapt our working style to reflect your needs

Real-world pharma experience

We have a wealth of practical knowledge & experience within the pharma industry & HTA bodies

Responsive

We react quickly and effectively to provide the best support possible

Updates & News

Latest research and publications

Articles
24.01.2024
What are the 5 Pricing & Market Access trends…

Our experts provide an overview of the five key trends that could shape the pricing and market acces…

Read more
News
16.11.2023
ISPOR Europe 2023

We’re thrilled to announce our participation at ISPOR Europe 2023 in Copenhagen this November. We’ll…

Read more
Insider Insights
16.02.2024
Biosimilar Switching in Germany from March 15, 202…

New biosimilar switching regulations prioritise cost-effective options and discount agreements, imp…

Read more
Articles
15.02.2024
PATT 2.0: NICE Priorities & Pharma Impact

We examine the effects on patient access, specifically regarding pathways, high value steps, multi-i…

Read more
Insider Insights
14.02.2024
NICE update: What manufacturers need to know about…

Our analysts explore NICE’s integration of tech appraisals into treatment guidelines for to enable o…

Read more
Articles
08.02.2024
Is the attractiveness of launch in the UK changing…

This expert article focusses on the new proportionate approach, and the international recognition pr…

Read more
Insider Insights
06.02.2024
Confidential rebates are raising concerns in Germa…

Proposed changes in Germany’s pharma strategy suggest replacing publicly listed AMNOG rebates with c…

Read more
Insider Insights
30.01.2024
AIFA regulatory overhaul marks milestone in Pharma

AIFA’s restructuring in Italy aims to streamline drug approval, replacing committees and introducing…

Read more
Insider Insights
30.01.2024
Financing of new orphan drugs in Spain increases i…

Spain seeks to enhance financing for orphan drug access, signalling a push for better timelines and …

Read more
Insider Insights
30.01.2024
NICE recommends Talazoparib for advanced breast ca…

NICE set to endorse talazoparib for adults with BRCA 1 or 2 mutated HER2-negative locally advanced o…

Read more
Insider Insights
30.01.2024
AML treatment Tibsovo earns key rating in Germany

Tibsovo (ivosidenib) has been granted a major additional benefit rating for its use as a first-line …

Read more
Visit our resource library

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.